This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Myriad Publishes Data On Its Variant Classification Program In Clinical Genetics

SALT LAKE CITY, Jan. 28, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has published details of its myVision™ Myriad Variant Classification Program in the journal Clinical Genetics. myVision is the most advanced variant classification program available to determine whether a patient's genetic variant (mutation) is benign or deleterious. myVision employs a number of robust scientific methods and is backed by Myriad's 20 years of clinical research and testing in more than one million patients.

"Patients who receive a genetic test that identifies a variant of uncertain significance (VUS) do not know if their mutation is benign or deleterious and associated with hereditary cancer risk. This lack of clarity is emotionally difficult and confusing for patients who are making medical decisions and may translate into substantial downstream healthcare costs," said Richard Wenstrup, M.D., chief medical officer at Myriad Genetics Laboratories. "Myriad has been a leader in the field of variant classification and has significantly reduced the VUS rate for patients of all ethnic groups."

Since 2002, Myriad's variant classification program has significantly lowered the VUS rate for all major ethnic groups by approximately tenfold. For example, among patients of African ancestry, the VUS rate was reduced from 38.6 percent to 3.6 percent and for patients with Latin ancestry, the VUS rate was lowered from 26.1 percent to 3 percent.

These unparalleled results are attributable to Myriad's investment in two proprietary statistical classification tools including Pheno™ and MCo™, which were developed using a validation set of more than 400,000 patients. These tools provide classification accuracy of greater than 99 percent, whereas some of the statistical methods used by others, such as Sift Poly Phen, have classification accuracies as low as 57 percent.  

Myriad has a lifetime commitment to provide the most up-to-date and accurate variant information to patients and their families. For example, the Company offers genetic testing at no cost to selected family members in order to clarify VUS results and reinforce previous findings. Myriad also continually evaluates new information as it emerges to classify VUS quickly and accurately. If a VUS is classified in the future, the Company sends this critical information to patients' healthcare providers at no additional cost to the patient.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,880.36 -31.75 -0.19%
S&P 500 1,970.07 +0.12 0.01%
NASDAQ 4,462.9020 +20.2040 0.45%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs